Identification and Characterization of CIM-1, a Carbapenemase That Adds to the Family of Resistance Factors Against Last Resort Antibiotics

Overview

Journal Commun Biol

Specialty Biology

Date 2024 Mar 7

PMID 38454015

Authors

Yu Wang

Sylvia A Sapula

Jonathan J Whittall

Jack M Blaikie

Olga Lomovskaya

Henrietta Venter

Affiliations

Soon will be listed here.

Abstract

The increasing rate of carbapenem-resistant bacteria within healthcare environments is an issue of great concern that needs urgent attention. This resistance is driven by metallo-β-lactamases (MBLs), which can catalyse the hydrolysis of almost all clinically available β-lactams and are resistant to all the clinically utilized β-lactamase inhibitors. In this study, an uncharacterized MBL is identified in a multidrug resistant isolate of the opportunistic pathogen, Chryseobacterium indologenes. Sequence analysis predicts this MBL (CIM-1) to be a lipoprotein with an atypical lipobox. Characterization of CIM-1 reveals it to be a high-affinity carbapenemase with a broad spectrum of activity that includes all cephalosporins and carbapenems. Results also shown that CIM-1 is potentially a membrane-associated MBL with an uncharacterized lipobox. Using prediction tools, we also identify more potentially lipidated MBLs with non-canonical lipoboxes highlighting the necessity of further investigation of lipidated MBLs.

References

Versporten A, Zarb P, Caniaux I, Gros M, Drapier N, Miller M . Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018; 6(6):e619-e629. DOI: 10.1016/S2214-109X(18)30186-4. View

Imai S, Inoue N, Nagai H . Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan. BMC Infect Dis. 2022; 22(1):581. PMC: 9241247. DOI: 10.1186/s12879-022-07548-3. View

Meletis G . Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016; 3(1):15-21. PMC: 4735501. DOI: 10.1177/2049936115621709. View

Izaguirre-Anariba D, Sivapalan V . Chryseobacterium indologenes, an Emerging Bacteria: A Case Report and Review of Literature. Cureus. 2020; 12(1):e6720. PMC: 7032597. DOI: 10.7759/cureus.6720. View

Alyami A, Kaabia N, AlQasim M, Al Doghaim F, Albehlal L, Ahmed M . Chryseobacterium/Elizabethkingia species infections in Saudi Arabia. Saudi Med J. 2020; 41(3):309-313. PMC: 7841570. DOI: 10.15537/smj.2020.3.24985. View

Calderon G, Garcia E, Rojas P, Garcia E, Rosso M, Losada A . Chryseobacterium indologenes infection in a newborn: a case report. J Med Case Rep. 2011; 5:10. PMC: 3025965. DOI: 10.1186/1752-1947-5-10. View

Hsieh M, Yang S, Liu Y, Lin C . Chryseobacterium indologenes keratitis-A case report. Kaohsiung J Med Sci. 2020; 36(7):563-564. DOI: 10.1002/kjm2.12195. View

Lambiase A, Del Pezzo M, Raia V, Sepe A, Ferri P, Rossano F . Chryseobacterium respiratory tract infections in patients with cystic fibrosis. J Infect. 2007; 55(6):518-23. DOI: 10.1016/j.jinf.2007.08.002. View

Fan J, Li X, Gao Y, Zhou J, Wang S, Huang B . The lung tissue microbiota features of 20 deceased patients with COVID-19. J Infect. 2020; 81(3):e64-e67. PMC: 7306202. DOI: 10.1016/j.jinf.2020.06.047. View

10.

Arzanlou M, Chai W, Venter H . Intrinsic, adaptive and acquired antimicrobial resistance in Gram-negative bacteria. Essays Biochem. 2017; 61(1):49-59. DOI: 10.1042/EBC20160063. View

11.

Palzkill T . Metallo-β-lactamase structure and function. Ann N Y Acad Sci. 2012; 1277:91-104. PMC: 3970115. DOI: 10.1111/j.1749-6632.2012.06796.x. View

12.

Lomovskaya O, Tsivkovski R, Sun D, Reddy R, Totrov M, Hecker S . QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Front Microbiol. 2021; 12:697180. PMC: 8287861. DOI: 10.3389/fmicb.2021.697180. View

13.

Brem J, Panduwawala T, Ulf Hansen J, Hewitt J, Liepins E, Donets P . Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors. Nat Chem. 2021; 14(1):15-24. DOI: 10.1038/s41557-021-00831-x. View

14.

Sun D, Tsivkovski R, Pogliano J, Tsunemoto H, Nelson K, Rubio-Aparicio D . Intrinsic Antibacterial Activity of Xeruborbactam : Assessing Spectrum and Mode of Action. Antimicrob Agents Chemother. 2022; 66(10):e0087922. PMC: 9578396. DOI: 10.1128/aac.00879-22. View

15.

Dortet L, Poirel L, Nordmann P . Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int. 2014; 2014:249856. PMC: 3984790. DOI: 10.1155/2014/249856. View

16.

Gonzalez L, Bahr G, Nakashige T, Nolan E, Bonomo R, Vila A . Membrane anchoring stabilizes and favors secretion of New Delhi metallo-β-lactamase. Nat Chem Biol. 2016; 12(7):516-22. PMC: 4912412. DOI: 10.1038/nchembio.2083. View

17.

Hayashi S, Wu H . Lipoproteins in bacteria. J Bioenerg Biomembr. 1990; 22(3):451-71. DOI: 10.1007/BF00763177. View

18.

Babu M, Priya M, Selvan A, Madera M, Gough J, Aravind L . A database of bacterial lipoproteins (DOLOP) with functional assignments to predicted lipoproteins. J Bacteriol. 2006; 188(8):2761-73. PMC: 1446993. DOI: 10.1128/JB.188.8.2761-2773.2006. View

19.

Kovacs-Simon A, Titball R, Michell S . Lipoproteins of bacterial pathogens. Infect Immun. 2010; 79(2):548-61. PMC: 3028857. DOI: 10.1128/IAI.00682-10. View

20.

Teufel F, Almagro Armenteros J, Johansen A, Gislason M, Pihl S, Tsirigos K . SignalP 6.0 predicts all five types of signal peptides using protein language models. Nat Biotechnol. 2022; 40(7):1023-1025. PMC: 9287161. DOI: 10.1038/s41587-021-01156-3. View